Authors: Masey Ross, Charles E. Geyer
Summary: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was approved in 2005 for the treatment of metastatic breast cancer, primarily on the basis of a phase III trial that compared every-3-week administration of nab-paclitaxel 260 mg/m2 as a 30-minute infusion with standard paclitaxel (s-paclitaxel) 175 mg/m2 as a 3-hour infusion. The primary end point of overall response rate was improved with nab-paclitaxel (33% v 19%), as was median time to tumor progression (23 v 16.9 weeks; Table 1). Although nab-paclitaxel provided a shorter infusion time and omission of premedication, it was associated with more grade 3 peripheral sensory neuropathy (PSN; 10% v 2%; P < .001) along with nausea and diarrhea.
Source: Journal of Clinical Oncology, 2019; JCO.19.00877